Global Lung Cancer Surgery Market Size To Exceed USD 9.92 Billion By 2033 | CAGR Of 5.32% [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Reach USD 9.92 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: Johnson & Johnson, Ethicon, Karl Storz SE & Co. KG, Medrobotics Corporation, Accuray Incorporated, Novartis AG, Boston Scientific Corporation, AngioDynamics, Becton, Dickinson and Company, Stryker Corporation, Olympus Corporation, Teleflex Incorporated, Siemens Healthineers AG, GE Healthcare, and other key vendors. New York, United States, June 25, 2024 (GLOBE NEWSWIRE) -- The Global Lung Cancer Surgery Market Size is to Grow from USD 5.91 Billion in 2023 to USD 9.92 Billion by 2033, at a CAGR of 5.32% during the projected period. Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/4642 Lung surgery is a choice for specific patients depending on the type, location, and stage of lung cancer and other medical issues. Surgery is used to try to treat lung cancer. Almost all surrounding lung tissue and frequently the lymph nodes near
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Nipocalimab pivotal Phase 3 trial demonstrates sustained disease control in FcRn class for a broad population of myasthenia gravis patients [Yahoo! Finance]Yahoo! Finance
- Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients [Yahoo! Finance]Yahoo! Finance
- Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patientsPR Newswire
- Registrations Open for the 2024 Orphan Drugs and Rare Diseases Conference - Boston, MA, United States - October 17-18th, 2024 [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/16/24 - Beat
JNJ
Sec Filings
- 6/25/24 - Form 11-K/A
- 6/24/24 - Form 11-K
- 6/24/24 - Form 11-K
- JNJ's page on the SEC website